1. The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils.
- Author
-
Dib K, Perecko T, Jenei V, McFarlane C, Comer D, Brown V, Katebe M, Scheithauer T, Thurmond RL, Chazot PL, and Ennis M
- Subjects
- Cell Adhesion drug effects, Cell Adhesion physiology, Cell Line, Tumor, Cell Shape drug effects, Cells, Cultured, Cytochalasin B pharmacology, Fibrinogen, Histamine pharmacology, Humans, Indoles pharmacology, Leukemia, Promyelocytic, Acute pathology, Lymphocyte Function-Associated Antigen-1 chemistry, MAP Kinase Signaling System drug effects, Macrophage-1 Antigen physiology, N-Formylmethionine Leucyl-Phenylalanine pharmacology, Neutrophils drug effects, Oximes pharmacology, Piperazines pharmacology, Piperidines pharmacology, Protein Conformation drug effects, Pyridines pharmacology, RNA, Messenger biosynthesis, RNA, Messenger genetics, Receptors, G-Protein-Coupled agonists, Receptors, G-Protein-Coupled antagonists & inhibitors, Receptors, Histamine H4, p38 Mitogen-Activated Protein Kinases physiology, Cell Degranulation drug effects, Neutrophils physiology, Receptors, G-Protein-Coupled physiology, Receptors, Histamine physiology
- Abstract
The histamine H4 receptor regulates the inflammatory response. However, it is not known whether this receptor has a functional role in human neutrophils. We found that fMLP (1 μM), but not histamine (0.1-1 μM), induced Mac-1-dependent adhesion, polarization, and degranulation (release of lactoferrin). A pretreatment of neutrophils with histamine (0.001-1 μM) or JNJ 28610244 (0.1-10 μM), a specific H4 receptor agonist, led to inhibition of degranulation. Total inhibition of degranulation was obtained with 0.1 μM histamine and 10 μM JNJ 28610244. Furthermore, such inhibition by histamine of degranulation was reversed by JNJ 7777120 and JNJ 28307474, two selective H4 receptor antagonists. However, neither histamine nor the H4 receptor agonist JNJ 28610244 prevented fMLP-induced, Mac-1-dependent adhesion, indicating that the H4 receptor may block signals emanating from Mac-1-controlling degranulation. Likewise, engagement of the H4 receptor by the selective agonist JNJ 28610244 blocked Mac-1-dependent activation of p38 MAPK, the kinase that controls neutrophil degranulation. We also show expression of the H4 receptor at the mRNA level in ultrapure human neutrophils and myeloid leukemia PLB-985 cells. We concluded that engagement of this receptor by selective H4 receptor agonists may represent a good, therapeutic approach to accelerate resolution of inflammation., (© 2014 Society for Leukocyte Biology.)
- Published
- 2014
- Full Text
- View/download PDF